Entering text into the input field will update the search result below

Scynexis up 11% on advancement of late-stage study of antifungal ibrexafungerp

Sep. 18, 2019 12:34 PM ETSCYNEXIS, Inc. (SCYX) StockSCYXBy: Douglas W. House, SA News Editor7 Comments
  • Thinly traded nano cap SCYNEXIS (SCYX +11%) is up on more than a 4x surge in volume in reaction to the completion of the last visit for the last patient in its Phase 3 clinical trial, VANISH 303, evaluating ibrexafungerp (formerly SCY-078) for  the treatment of fungal infections, in both outpatient and inpatient settings. Topline data should be available by year-end.
  • A data readout from a second Phase 3, VANISH 306, should also be available in Q2 2020.
  • If all goes well, the company expects to file a U.S. marketing application in H2 2020.

Recommended For You

About SCYX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SCYX--
SCYNEXIS, Inc.